BN Business News
Add your company to Business Communicator →

Business · 22/12/1994

NIH to Grant Exclusive License for Neutralizing Monoclonal Antibodies Against Respiratory Syncytial Virus

The National Institutes of Health (NIH) is considering granting an exclusive worldwide license to SmithKline Beecham Corporation to develop and commercialize neutralizing monoclonal antibodies for treating and preventing Respiratory Syncytial Virus (RSV) infections in humans, with the potential for royalty-bearing revenue.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights